Literature DB >> 23719603

Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.

Jiong Chen1, Wen Wu, Longjiang Chen, Hangcheng Zhou, Renbao Yang, Liwei Hu, Yue Zhao.   

Abstract

BACKGROUND/AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with an increasing incidence worldwide. Due to lack of early diagnosis and poor prognosis, it is rather critical to improve the early diagnosis of PDAC. A comparative proteomic method was used to analyze serum proteins to find a new potential specific marker.
METHODS: Comparative analysis of the pancreatic peripheral blood protein profiling from 40 pancreatic cancer patients, 10 pancreatic benign tumor patients, 10 chronic pancreatitis patients and 40 cancer-free controls. The samples were carried out by 2D-differential gel electrophoresis (2D-DIGE) and differentially expressed proteins were identified by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). Two up-regulated proteins were further validation by real time RT-PCR, Western blot analysis and Immunohistochemistry (IHC).
RESULTS: We identified fourteen differently expressed proteins in PDAC group compared with cancer-free control group, including 9 up-regulation and 5 down-regulation proteins. Increased Complement C3 and alpha-2-HS-glycoprotein (AHSG) were further confirmed by real time RT-PCR, Western blot analysis and IHC. The expressions of Complement C3 and AHSG were higher in PDAC than that in other groups.
CONCLUSIONS: These results suggest that Complement C3 and AHSG might be the potential tumor markers in PDAC screening and diagnosis. The finding of inflammation mediated factor Complement C3 revealed that inflammation might be closely related with the occurrence and development process of PDAC.
Copyright © 2013 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23719603     DOI: 10.1016/j.pan.2013.03.010

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  14 in total

Review 1.  Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes.

Authors:  Josiah Ochieng; Gladys Nangami; Amos Sakwe; Cierra Moye; Joel Alvarez; Diva Whalen; Portia Thomas; Philip Lammers
Journal:  Int J Mol Sci       Date:  2018-07-29       Impact factor: 5.923

Review 2.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

3.  Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer.

Authors:  Paul J Mintz; Anna Cecilia Rietz; Marina Cardó-Vila; Michael G Ozawa; Eleonora Dondossola; Kim-Anh Do; Jeri Kim; Patricia Troncoso; Christopher J Logothetis; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

4.  FN1 encoding fibronectin as a pivotal signaling gene for therapeutic intervention against pancreatic cancer.

Authors:  Gayathri Ashok; Sravan Kumar Miryala; Megha Treesa Saju; Anand Anbarasu; Sudha Ramaiah
Journal:  Mol Genet Genomics       Date:  2022-08-18       Impact factor: 2.980

Review 5.  Inside-Out of Complement in Cancer.

Authors:  Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M Markiewski
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

6.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01

7.  Proteomic profiling of retinoblastoma by high resolution mass spectrometry.

Authors:  Ravikanth Danda; Kalaivani Ganapathy; Gajanan Sathe; Anil K Madugundu; Sharavan Ramachandran; Uma Maheswari Krishnan; Vikas Khetan; Pukhraj Rishi; T S Keshava Prasad; Akhilesh Pandey; Subramanian Krishnakumar; Harsha Gowda; Sailaja V Elchuri
Journal:  Clin Proteomics       Date:  2016-10-26       Impact factor: 3.988

8.  Fetuin-A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high-grade astrocytomas.

Authors:  Gladys N Nangami; Amos M Sakwe; Michael G Izban; Tanu Rana; Philip E Lammers; Portia Thomas; Zhenbang Chen; Josiah Ochieng
Journal:  Cancer Med       Date:  2016-11-23       Impact factor: 4.452

Review 9.  A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.

Authors:  Sara S Faria; Carlos F M Morris; Adriano R Silva; Micaella P Fonseca; Patrice Forget; Mariana S Castro; Wagner Fontes
Journal:  Front Oncol       Date:  2017-02-20       Impact factor: 6.244

Review 10.  Complement in Pancreatic Disease-Perpetrator or Savior?

Authors:  Lucas Bettac; Stephanie Denk; Thomas Seufferlein; Markus Huber-Lang
Journal:  Front Immunol       Date:  2017-01-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.